We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
These days, hep C isn’t looking like the cash cow market it once was, prompting some of those trailing behind leader Gilead to bail on their development programs.